Abstract
Physical activity is favorable to health but the relations with human disease and causal effects are poorly quantified. Previous studies have largely relied on self-reported estimates1–3 which are subject to recall bias, confounding, and reverse causality. Using wrist-worn accelerometer measurements from the UK Biobank, we tested associations between moderate-to-vigorous physical activity (MVPA) – both total MVPA minutes and whether MVPA was above a guideline-based threshold of ≥150 minutes/week4–6 – and incidence of over 1,200 diseases. In 96,466 adults who wore accelerometers for one week (mean age 62±8 years), MVPA was associated with 401 (33%) tested diseases at a false discovery rate of 1% during a median of 6.2 years follow-up. Greater MVPA was overwhelmingly associated with reduced disease risk (98% of associations) with hazard ratios (HRs) ranging from 0.10-0.95 per standard deviation (SD) and associations spanning all 18 disease categories tested. A similar pattern of associations was observed when assessing the guideline-based threshold of ≥150 MVPA minutes/week. We examined a polygenic risk score for MVPA as an instrumental variable for activity within a separate UK Biobank sample (N=392,058, mean age 57±8 years). Greater genetically inferred MVPA was associated with reduced risk of 182 (14%) incident diseases (HR range 0.74-0.97 per 1 SD), and included strong associations conferring reduced risks of obstructive bronchitis, peripheral vascular disease, type 2 diabetes, and gastritis/duodenitis. Objective physical activity is broadly associated with lower disease incidence and many associations are consistent with a causal effect.
Competing Interest Statement
Dr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG, and participates in a research collaboration with IBM. Dr. Ellinor receives sponsored research support from Bayer AG and IBM Health and he has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics.
Funding Statement
Dr. Khurshid is supported by NIH T32HL007208. Dr. Nauffal is supported by NIH T32HL007604. Dr. Ellinor is supported by the NIH grants 1RO1HL092577 and K24HL105780, and American Heart Association 18SFRN34110082. Dr. Lubitz is supported by NIH 1R01HL139731 and American Heart Association 18SFRN34250007. Dr. Benjamin is supported by R01HL092577, R01HL141434, R01AG066010; 1R01AG066914, 2U54HL120163, and American Heart Association 18SFRN34110082. Dr. Weng is supported by American Heart Association 18SFRN34110082.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent. The UK Biobank was approved by the UK Biobank Research Ethics Committee (reference# 11/NW/0382). Use of UK Biobank data (application 17488) was approved by the local Mass General Brigham Health Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data are freely available for research purposes by application (https://www.ukbiobank.ac.uk/). Data processing scripts used to perform the analyses described herein can be found at (https://github.com/shaankhurshid/acceleration_phewas). Detailed summary data supporting major study results are provided in the Supplementary Data.
